title: Pregnancy during adalimumab use for psoriasis.
authors.forename: C
authors.initials: C
authors.lastname: Dessinioti
authors.forename: I
authors.initials: I
authors.lastname: Stefanaki
authors.forename: A J
authors.initials: AJ
authors.lastname: Stratigos
authors.forename: M
authors.initials: M
authors.lastname: Kostaki
authors.forename: A
authors.initials: A
authors.lastname: Katsambas
authors.forename: C
authors.initials: C
authors.lastname: Antoniou
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002585:Cesarean Section; D005260:Female; D006801:Humans; D050498:Live Birth; D011247:Pregnancy; D011256:Pregnancy Outcome; D049168:Pregnancy, Unplanned; D011565:Psoriasis / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab